Significantly lower risk is seen for cases and viral clearance. 2 studies (both from the same team) show significant benefit.
Meta analysis using the most serious outcome reported shows 49% [-60‑84%] lower risk, without reaching statistical significance.
Currently there is limited data, with only 345 patients in trials to date. All studies to date are from the same group.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. HH-120 currently has no early treatment studies. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Jan 2025, preprint, 1 author.
